

**From:** Maruna, Thomas  
**Sent:** Monday, March 07, 2016 12:59 PM  
**To:** 'Angela.Azzara@cslbehring.com'; KevinDarryl.White@cslbehring.com  
**Cc:** Baum, Victor  
**Subject:** March 7. 2016 Information Request - BLA 125591.0 - Please Respond By March 9. 2016

**Importance:** High

CSL Behring Recombinant Facility AG  
Attention: Mr. Kevin Darryl White  
March 7, 2016  
Sent by email

Dear Mr. White:

We are reviewing your May 29, 2015 biologics license application (BLA) for the following:

<b>STN</b>	<b>Name of Biological Products</b>
125591/0	Antihemophilic Factor (Recombinant), Single Chain

We have reviewed amendment 25 to BLA 125591, which represents labeling changes to reflect the final pediatric data in CSL627\_3002. Table 6 of that label reports on the pharmacokinetic parameters of 39 children who received Afstyla 50 IU/kg. In our review it appears that there were 38 appropriate subjects for this analysis. See, e.g. Tables 11-8 and 11-9 on pages 82 and 83 of the final Clinical Study Report for CSL627\_3002.

Subject (b) (6) received an actual dose of 56.4 IU per kg, beyond the allowable tolerance limit of  $\pm 10\%$ .

Please explain why this subject's data should not be excluded from Table 6 of the label.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your responses as an amendment to this file by March 9, 2016 referencing the date of this request.

The action due date for this file is May 28, 2016.

If you have any questions, please contact me.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP), CPH

Lieutenant, U.S. Public Health Service  
Senior Regulatory Management Officer  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
Office of Blood Research and Review  
10903 New Hampshire Ave.  
Silver Spring, MD 20993  
[thomas.maruna@fda.hhs.gov](mailto:thomas.maruna@fda.hhs.gov)  
O: (240) 402-8454  
[www.usphs.gov](http://www.usphs.gov)



"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.